Gefitinib-based PROTAC 3 is primarily used in targeted protein degradation research, particularly in cancer studies. It is designed to selectively degrade specific proteins involved in cancer cell proliferation and survival. By leveraging the PROTAC (Proteolysis Targeting Chimera) technology, it binds to the target protein and recruits an E3 ubiquitin ligase, marking the protein for proteasomal degradation. This approach is especially valuable in overcoming drug resistance in certain cancers, as it directly eliminates the proteins responsible for resistance mechanisms. Its application is being explored in preclinical models to evaluate its efficacy in degrading oncogenic proteins and inhibiting tumor growth.